Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/146371
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | RENAAL Study Investigators |
dc.contributor.author | Martínez Castelao, Alberto |
dc.date | 2019-12-10T12:38:49Z |
dc.date | 2019-12-10T12:38:49Z |
dc.date | 2000-12-01 |
dc.date | 2019-12-10T12:38:50Z |
dc.identifier.citation | 1470-3203 |
dc.identifier.citation | 522638 |
dc.identifier.uri | http://hdl.handle.net/2445/146371 |
dc.format | 8 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation | Reproducció del document publicat a: https://doi.org/10.3317/jraas.2000.062 |
dc.relation | Journal of the Renin-Angiotensin-Aldosterone System , 2000, vol. 1, num. 4, p. 328-335 |
dc.relation | https://doi.org/10.3317/jraas.2000.062 |
dc.rights | cc-by-nc (c) RENAAL Study Investigators et al., 2000 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by-nc/3.0/es |
dc.subject | Angiotensines |
dc.subject | Ronyó |
dc.subject | Angiotensins |
dc.subject | Kidney |
dc.title | The Losartan renal Protection study. Rational study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |